English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background    Anaplastic lymphoma kinase  ( ALK ) rearrangements define a subgroup of lung cancer which is eligible to targeted kinase inhibition. The aim of this study is to observe the incidence rate of ALK fusion in a large cohort of Chinese digestive tract cancer patients.    Patients and Methods  Tissue microarray (TMA) was constructed from 808 digestive tract cancer cases, including 169 esophageal squamous cell carcinoma, 182 gastric cancer and 457 colorectal cancer (CRC) cases. We tested all cases for ALK expression via a fully automated immunohistochemistry (IHC) assay. The IHC-positive cases were subjected to fluorescence  in situ  hybridization (FISH), real-time polymerase chain reaction (qRT-PCR), target gene enrichment and sequencing for confirmation of  ALK  gene rearrangement and discovery of novel fusion partner.    Results  Among the tested cases, 2 (0.44%) CRC cases showed positive both by IHC and FISH. By qRT-PCR,  EML4–ALK  fusion was found in one IHC-positive CRC case. In another IHC-positive CRC case, target gene enrichment and sequencing revealed  ALK  was fused to a novel partner,  spectrin beta non-erythrocytic 1  ( SPTBN1 ). One gastric cancer case showed partially positive IHC result, but no fusion was found by FISH and gene sequencing.    Conclusions  The incidence rate of  ALK  gene fusion in Chinese CRC patients was 0.44%,but not detectable in gastric and esophageal cancers. The novel  SPTBN1 -ALK  fusion, together with other  ALK  fusion genes, may become a potential target for anti-ALK therapy.

Anaplastic Lymphoma Kinase Rearrangement in Digestive Tract Cancer: Implication for Targeted Therapy in Chinese Population